These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 26298521

  • 1. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
    Wada N, Mori K, Nakagawa C, Sawa J, Kumeda Y, Shoji T, Emoto M, Inaba M.
    J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W, Ueno H, Yamashita E, Tsubouchi C, Sakoda H, Nakamura S, Nakazato M.
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
    Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K.
    Diabetes Res Clin Pract; 2016 Dec; 122():78-83. PubMed ID: 27810689
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T, Haneda M, Ito H, Sasaki K, Yamada Y.
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [Abstract] [Full Text] [Related]

  • 11. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of Glycemic Markers in Chronic Hemodialysis Using Continuous Glucose Monitoring.
    Divani M, Georgianos PI, Didangelos T, Iliadis F, Makedou A, Hatzitolios A, Liakopoulos V, Grekas DM.
    Am J Nephrol; 2018 Sep; 47(1):21-29. PubMed ID: 29275415
    [Abstract] [Full Text] [Related]

  • 14. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y, Okamura K, Shirai K, Okuda T, Kobayashi K, Urata H.
    Clin Exp Hypertens; 2020 Sep; 42(3):197-204. PubMed ID: 30974980
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y.
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
    Kamiko K, Aoki K, Kamiyama H, Taguri M, Shibata E, Ashiya Y, Minagawa F, Shinoda K, Nakajima S, Terauchi Y.
    J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
    [Abstract] [Full Text] [Related]

  • 17. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
    Kadowaki T, Haneda M, Ito H, Sasaki K, Hiraide S, Matsukawa M, Ueno M.
    Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
    Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, Takashima H, Kikuchi F, Tomita H, Okada K.
    Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
    [Abstract] [Full Text] [Related]

  • 19. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
    Chan CL, Pyle L, Kelsey MM, Newnes L, Baumgartner A, Zeitler PS, Nadeau KJ.
    Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
    [Abstract] [Full Text] [Related]

  • 20. Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system.
    Jung HS, Kim HI, Kim MJ, Yoon JW, Ahn HY, Cho YM, Oh KH, Joo KW, Lee JG, Kim SY, Park KS.
    Diabetes Technol Ther; 2010 Oct; 12(10):801-7. PubMed ID: 20809681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.